Major R&D Pipeline: 3ADCs

Revenue: Business Units (incl. Forex Impact) Japan Business Daiichi Sankyo Healthcare Oncolgy Business Enhertu Turalio American Regent Injectafer Venofer GE injectables EU Speciality Business Lixiana Nilemdo/Nustendi Olmesartan ASCA (Asia, South and Central America) Currency Rate (Bn JPY) FY2020 Q1 FY2021 Q1 YOY Results Results 130.2 129.1 -1.1 14.3 15.4 +1.1 11.6 14.5 +2.9 5.0 10.8 +5.8 0.3 0.6 +0.3 26.5 39.1 +12.6 9.4 14.9 +5.4 6.9 7.9 +1.0 8.5 13.8 +5.3 27.7 32.7 +5.0 16.4 23.4 +7.0 - 0.7 +0.7 5.2 5.6 +0.4 22.5 26.5 +3.9 Daiichi-Sankyo USD/JPY 107.62 109.49 +1.87 EUR/JPY 118.47 131.95 +13.48 8

View entire presentation